Intelligence / Healthtech / New Clinical Trials / CASI pharmaceuticals, Inc.
Clinicaltrial registered18 Nov 2026
CASI pharmaceuticals, Inc.
18 Nov 2026: Trial registered · A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 18 Nov 2026
- Title
- A Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
- Conditions
- Chronic Immune Thrombocytopenia
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07946549
- Location
- China
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at CASI pharmaceuticals, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from China
New Clinical Trials
18 NovBeijing Baheal Wisart Medical Research Co., Ltdtrial registered · Safety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Dose of YY524051 Tablets in Healthy Adults.Clinical18 NovBeijing Xunsheng Biomedical Research Co., Ltd.trial registered · Safety, Tolerability, and Efficacy of a Therapeutic Intervention for HPV16/18 InfectionClinical18 NovEli Lilly and Companytrial registered · A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3839056 in Healthy ParticipantsClinical18 NovFujian Akeylink Biotechnology Co., Ltd.trial registered · A Study on the Pharmacokinetics and Safety of GST-HG141 Tablets in Participants With Hepatic Impairment and Normal Liver FunctionClinical18 NovGan & Lee Pharmaceuticals.trial registered · A Pharmacokinetics Study of GZR33 Injection at Different Injection SitesClinical18 NovLongbio Pharmatrial registered · A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 AntihistaminesClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.